{
    "code": "22000014",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=22000014",
    "time": "2018-11-30 03:36:36",
    "許可證字號": "罕菌疫輸字第000014號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "111\/08\/27",
    "發證日期": "101\/08\/27",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA02200001409",
    "中文品名": "泰吉利濃縮靜脈輸注液 300 毫克",
    "英文品名": "Tysabri concentrate for solution for infusion 300mg",
    "適應症": "單一藥物治療反覆發作型多發性硬化症,其病患群為下列18歲以上之成人患者:(1)已使用β-interferon治療,但是無法有效控制病情的反覆發作型多發性硬化症病患或(2)病情急速惡化的反覆發作型多發性硬化症患者。",
    "劑型": "270注射劑",
    "包裝": "15毫升小瓶",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "Natalizumab"
    ],
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "0407901100  衛采製藥股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F470559000  VETTER PHARMA-FERTIGUNG GMBH &amp; CO KG",
        "製造廠廠址": "MOOSWIESEN 2, 88214 RAVENSBURG, GERMANY",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F110047100  BIOGEN DENMARK MANUFACTURING APS",
            "製造廠廠址": "BIOGEN ALLE 1, DK-3400 HILLEROD, DENMARK",
            "製造廠公司地址": "",
            "製造廠國別": "DENMARK",
            "製程": "原料藥製造廠及包裝廠"
        },
        {
            "製造廠名稱": "F430123000  BIOGEN INTERNATIONAL GMBH",
            "製造廠廠址": "LANDIS &amp; GYR STRASSE 3 6300 ZUG - SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "許可證持有者"
        },
        {
            "製造廠名稱": "F460785000  BIOGEN INC.",
            "製造廠廠址": "5000 DAVIS DRIVE, RESEARCH TRIANGLE PARK, NORTH CAROLINA 27709, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013003400",
            "成分名稱": "Natalizumab",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "41151-05 COM PAT INF INSERT LARGE TYSABRI CONC 300MG TWN_P2_T_1-107-11-02(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=006&Type=9"
        },
        {
            "title": "41151-05 COM PAT INF INSERT LARGE TYSABRI CONC 300MG TWN_P2_T-107-03-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=005&Type=9"
        },
        {
            "title": "中文Tysabri PI TW 2016 EMEA version 20170629-106-06-29.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=003&Type=9"
        },
        {
            "title": "41155-04 COM LABEL VIAL TYSABRI CONC 300MG HLR TWN_P1_T-107-03-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=009&Type=8"
        },
        {
            "title": "41154-05 COM CARTON MPL 1PK TYSABRI CONC 300MG TWN_P1_T-107-03-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=008&Type=8"
        },
        {
            "title": "41152-06 COM CARTON APL 1PK TYSABRI CONC 300MG TWN_P1_T-107-03-05(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=007&Type=8"
        },
        {
            "title": "LABEL VIAL TYSABRI CONC 300MG @HLR TWN_P1 TFDAAPP-105-08-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=22000014&Seq=003&Type=8"
        }
    ]
}